Canada’s life sciences sector faces a critical drain of intellectual property and capital as promising firms are consistently sold to foreign buyers. Natalie Yeadon, founder and CEO of Augmentios, proposes a strategic blueprint with multiple priority reforms to transform public procurement, capital and tax structures, talent, drug reimbursement and health data, aiming to keep high-growth companies and their economic benefits within Canada.